



## STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER / NINE MONTHS ENDED DECEMBER 31, 2016

Sl. No.	Particulars	Three months ended			Nine Months ended			Year ended
		31/12/2016 (Unaudited)	30/09/2016 (Unaudited)	31/12/2015 (Unaudited)	31/12/2016 (Unaudited)	31/12/2015 (Unaudited)	31-Mar-2016 (Audited)	
1	<b>Income from Operations</b>							
	a) Net Sales / Income from Operations	17,727.26	18,359.22	20,401.51	54,531.54	67,199.39	87,666.17	
	b) Other Operating Income	271.02	414.21	186.45	1,608.82	845.25	1,322.39	
	<b>Total Income from Operations (net)</b>	17,998.28	18,773.43	20,587.96	56,140.36	68,044.64	88,988.56	
2	<b>Expenses</b>							
	a) Cost of Materials consumed	9,498.12	8,048.28	7,973.86	24,699.66	29,567.76	36,701.01	
	b) Purchases of Stock-in-Trade	182.92	611.05	320.76	2,566.62	3,680.55	3,701.23	
	c) Changes in inventories of Finished goods, Work-in-progress and Stock-in-trade	(2,207.38)	(116.69)	1,665.98	(155.00)	(291.99)	1,528.82	
	d) Employee benefits expense	1,957.54	1,968.83	2,138.81	5,795.18	6,579.21	8,263.08	
	e) Depreciation and Amortisation expense	3,524.06	3,474.21	3,584.34	10,449.53	10,836.24	14,341.22	
	f) Other Expenses	5,041.36	4,901.21	4,626.83	14,121.85	14,366.80	19,844.52	
	<b>Total Expenses</b>	17,996.62	18,886.89	20,310.58	57,477.84	64,738.57	84,379.88	
3	<b>Profit / (Loss) from Operations before Other Income, Finance cost and Exceptional Items (1-2)</b>	1.66	(113.46)	277.38	(1,337.48)	3,306.07	4,608.68	
4	Other Income	623.19	-	-	623.19	0.93	916.69	
5	<b>Profit / (Loss) from Ordinary activities before Finance cost and Exceptional Items (3+4)</b>	624.85	(113.46)	277.38	(714.29)	3,307.00	5,525.37	
6	Finance costs	6,942.97	7,123.82	7,613.55	20,985.19	22,288.80	29,423.18	
7	<b>Profit/(loss) from Ordinary activities after Finance costs but before Exceptional Item (5+6)</b>	(6,318.12)	(7,237.28)	(7,336.17)	(21,699.48)	(18,981.80)	(23,897.81)	
8	Exceptional Item - Gain/(Loss)	(999.45)	(817.13)	(1,366.23)	(2,870.30)	(3,892.22)	(5,254.53)	
9	<b>Profit/(Loss) before Tax (9+10) from Ordinary activities before Tax (7+8)</b>	(7,317.57)	(8,054.41)	(8,702.40)	(24,569.78)	(22,874.02)	(29,152.34)	
10	Tax expense	(1,219.68)	(1,202.42)	700.00	(3,617.83)	(1,821.07)	(1,725.07)	
11	<b>Net Profit/(Loss) from Ordinary activities after Tax (9 ± 10)</b>	(6,097.89)	(6,851.99)	(9,402.40)	(20,951.95)	(21,052.95)	(27,427.27)	
12	Extra-ordinary items - Gain/(Loss) (net of tax)	-	-	-	(8,625.85)	-	-	
13	<b>Net Profit/(Loss) for the period (11 ± 12)</b>	(6,097.89)	(6,851.99)	(9,402.40)	(29,577.80)	(21,052.95)	(27,427.27)	
14	Paid-up Equity Share Capital (Face value of Rs.10/- each)	8,896.43	8,896.43	8,896.43	8,896.43	8,896.43	8,896.43	
15	Reserves excluding Revaluation Reserves	-	-	-	-	-	-	
16	Earnings per share (EPS) before extra-ordinary items (of Rs.10 each)							
	- Basic Rs.*	(6.85)	(7.70)	(10.57)	(23.55)	(23.66)	(31.51)	
	- Diluted Rs.*	(6.85)	(7.70)	(10.57)	(23.55)	(23.66)	(31.51)	
17	Earnings per share (EPS) after extra-ordinary item (of Rs.10 each)							
	- Basic Rs.*	(6.85)	(7.70)	(10.57)	(33.25)	(23.66)	(31.51)	
	- Diluted Rs.*	(6.85)	(7.70)	(10.57)	(33.25)	(23.66)	(31.51)	

\* EPS for the period (not annualised)

See accompanying note to the Financial Results




## STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER / NINE MONTHS ENDED DECEMBER 31, 2016

- 1 The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 07, 2017.
- 2 The Company is operating in a single segment (i.e) "Pharmaceuticals".
- 3 Exceptional items for quarter ended December 31, 2016 represents amortisation of exchange loss on restatement of Foreign currency loans amounting to Rs.999.45 Lakhs (Corresponding previous quarter ended December 31,2015 Rs.1,366.23 Lakhs )
- 4 The Company had exercised the option provided under the Companies (Accounting Standards) Amendment Rules, 2006 dated March 31, 2009. The Ministry of Corporate affairs vide notification dated 29/12/2011 has extended the amortisation of gains or losses arising on reporting of foreign currency monetary items over the balance period of such long term asset/liability. Accordingly exchange loss on long term foreign currency loans have been amortised over the balance period of such loans. The amount remaining to be amortised on account of exercising the above option is Rs.9,354.47 Lakhs.
- 5 Interest expenses for the quarter ended December 31, 2016 is net of interest earned Rs.367.79 Lakhs (Corresponding previous quarter ended December 31, 2015 Rs.305.29 Lakhs).
- 6 Other income for the three months and nine months ended December 31, 2016 includes reversal of excess remuneration paid to Managing Director amounting to Rs.616.71 Lakhs for FY 2012-13 (consisting of 18 months) due to non receipt of approval from Central Government.
- 7 Extra-ordinary item for the nine months ended December 31, 2016 represents write-off of hold back money and inventory related to Transfer of Penam and Penicillin Business during July 2014.
- 8 The auditors have observed matters relating to recovery of certain advances paid to suppliers and non-provision of diminution in value of investments in foreign R&D subsidiaries. The Corporate Debt Restructuring scheme already approved has been implemented in July 2014. Due to financial constraints, the Company was not able to take delivery of materials/capital goods. The company is confident that it would be able to take delivery of these materials/capital goods in due course, based on its performance. In December 2015, the Company, through its subsidiary, has entered in to a long term financial arrangement which will help the Company explore new growth opportunities while enabling the current business achieve incremental value. This will also enable the Company to fulfill all capital commitments and take delivery of the materials / capital goods / adjust the advances. As far as the diminution in value of investments is concerned, the Management is confident that the value of intellectual property of molecules held by the foreign subsidiaries will be more than the investment. Hence the Board of Directors considering the explanation given by the Management is of the opinion that the observations made by the auditors will not have any material impact on the financials.

9 Previous period figures have been regrouped wherever necessary.

Place : Chennai

Date : February 07, 2017



For and on behalf of the Board

K. Raghavendra Rao  
Managing Director

